المؤلفون: Wilfried Rossoll, Ravindra N. Singh

المصدر: Frontiers in Cellular Neuroscience, Vol 16 (2022)

مصطلحات موضوعية: spinal muscular atrophy (SMA), Survival Motor Neuron (SMN), onasemnogene abeparvovec, Zolgensma, AVXS-101, gene therapy, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fncel.2022.916065/full; https://doaj.org/toc/1662-5102

URL الوصول: https://doaj.org/article/7de8661bee6e467bbd6347ba1764a483

المؤلفون: Dabbous, Omar, Maru, Benit, Jansen, Jeroen P., Lorenzi, Maria, Cloutier, Martin, Guérin, Annie, Pivneva, Irina, Wu, Eric Q., Arjunji, Ramesh, Feltner, Douglas, Sproule, Douglas M.^Aff1

المصدر: Advances in Therapy. 36(11):2982-2985

المؤلفون: Sandrock, Alfred W., Farwell, Wildon^Aff1

المصدر: Advances in Therapy. 36(11):2979-2981

المؤلفون: Dabbous, Omar, Maru, Benit, Jansen, Jeroen P., Lorenzi, Maria, Cloutier, Martin, Guérin, Annie, Pivneva, Irina, Wu, Eric Q., Arjunji, Ramesh, Feltner, Douglas, Sproule, Douglas M.^Aff1

المصدر: Advances in Therapy. 36(5):1164-1176

المؤلفون: Daniel C. Malone, Rebecca Dean, Ramesh Arjunji, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Omar Dabbous

المصدر: Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)

مصطلحات موضوعية: avxs-101, cost-effectiveness, gene-replacement therapy, nusinersen, onasemnogene abeparvovec, spinal muscular atrophy type 1, Public aspects of medicine, RA1-1270, Business, HF5001-6182

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2001-6689

URL الوصول: https://doaj.org/article/930a9177e655400d90828ef1a4362fd9

المؤلفون: Broekhoff, Thomas F., Sweegers, Carly C.G., Krijkamp, Eline M., Mantel-Teeuwisse, Aukje K., Leufkens, Hubert G.M., Goettsch, Wim G., Vreman, Rick A., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

المساهمون: Epidemiology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

المصدر: Value in Health, 24(6), 759-769. Elsevier Ltd.
Value in Health, 24(6), 759. Elsevier Ltd

مصطلحات موضوعية: Male, Comparative Effectiveness Research, Pediatrics, Technology Assessment, Biomedical, Time Factors, Cost effectiveness, Cost-Benefit Analysis, Health Status, Oligonucleotides, Zolgensma, Spinal Muscular Atrophies of Childhood, Recurrence, health care economics and organizations, spinal muscular atrophy, Netherlands, relapse, Clinical Trials as Topic, Health Policy, SMA, gene therapy, Models, Economic, Treatment Outcome, Female, Nusinersen, advanced therapy medicinal product, Public Health, Quality-Adjusted Life Years, After treatment, medicine.medical_specialty, Recombinant Fusion Proteins, Drug Costs, SDG 3 - Good Health and Well-being, medicine, AVXS-101, Humans, Treatment effect, health technology assessment, cost-effectiveness, Sensitivity analyses, Biological Products, business.industry, Environmental and Occupational Health, microsimulation, Public Health, Environmental and Occupational Health, Infant, Genetic Therapy, Spinal muscular atrophy, medicine.disease, Reference values, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e703a5dc1fe0fbc7b7c3fe5e434c6ba
https://doi.org/10.1016/j.jval.2020.09.021

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Maria Lorenzi, Jeroen P. Jansen, O. Dabbous, Benit Maru, Annie Guerin, Douglas M. Sproule, Douglas E. Feltner, Ramesh Arjunji, Irina Pivneva, Eric Q. Wu, Martin Cloutier

المصدر: Advances in Therapy

مصطلحات موضوعية: Onasemnogene abeparvovec-xioi, medicine.medical_specialty, Letter, Letter to the editor, business.industry, Pharmacology toxicology, Oligonucleotides, MEDLINE, Infant, General Medicine, Spinal muscular atrophy, NNT, Muscular Atrophy, Spinal, Clinical trial, Nusinersen, Family medicine, medicine, Humans, AVXS-101, Pharmacology (medical), business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ef95c92834f6943987e3169245a13dc
https://doi.org/10.1007/s12325-019-01088-0

المؤلفون: Douglas E. Feltner, Irina Pivneva, Martin Cloutier, Eric Q. Wu, Ramesh Arjunji, O. Dabbous, Annie Guerin, Douglas M. Sproule, Benit Maru, Jeroen P. Jansen, Maria Lorenzi

المصدر: Advances in Therapy

مصطلحات موضوعية: 030213 general clinical medicine, medicine.medical_specialty, Sitting, 03 medical and health sciences, 0302 clinical medicine, Nusinersen, Internal medicine, Onasemnogene abeparvovec, AVXS-101, Medicine, Pharmacology (medical), Original Research, business.industry, General Medicine, Spinal muscular atrophy, medicine.disease, SMA, Confidence interval, Clinical trial, 030220 oncology & carcinogenesis, Relative risk, Number needed to treat, Indirect treatment comparison, Spinal muscular atrophy type 1 (SMA type 1), business, Neuroscience

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e36535eccac12d04ad591848174ebad0
https://doi.org/10.1007/s12325-019-00923-8